NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $99.69 -3.34 (-3.24%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$98.75 -0.94 (-0.94%) As of 03/10/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Sarepta Therapeutics Stock (NASDAQ:SRPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$98.82▼$102.1550-Day Range$99.69▼$127.8952-Week Range$98.82▼$173.25Volume1.64 million shsAverage Volume923,232 shsMarket Capitalization$9.67 billionP/E Ratio79.75Dividend YieldN/APrice Target$170.41Consensus RatingModerate Buy Company OverviewSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreSRPT MarketRank™: Sarepta Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 30th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 18 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth309.74% Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 79.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 79.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.92.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 10.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.58% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 2.57%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.65 Percentage of Shares Shorted5.58% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 2.57%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.58 News SentimentSarepta Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.Search Interest23 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 92% compared to the previous 30 days.MarketBeat Follows9 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,310,820.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock News HeadlinesSolid Biosciences Soars 32% on Trial Data: 189% Upside from Here? (SRPT)Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?February 19, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Research Coverage Started at ScotiabankMarch 10 at 1:57 AM | americanbankingnews.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.March 11, 2025 | Stansberry Research (Ad)Scotiabank Initiates Coverage of Sarepta Therapeutics (SRPT) with Sector Perform RecommendationMarch 8 at 8:01 PM | msn.comA Closer Look At Sarepta Therapeutics' EarningsMarch 7, 2025 | finance.yahoo.comSpotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4March 4, 2025 | msn.comSarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock WeaknessMarch 4, 2025 | seekingalpha.comSarepta files automatic mixed securities shelfMarch 3, 2025 | markets.businessinsider.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $121.59 at the beginning of 2025. Since then, SRPT stock has decreased by 18.0% and is now trading at $99.69. View the best growth stocks for 2025 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.06. Sarepta Therapeutics's quarterly revenue was up 38.9% compared to the same quarter last year. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional shareholders include Vanguard Group Inc. (9.51%), Capital International Investors (9.11%), Janus Henderson Group PLC (4.53%) and Farallon Capital Management LLC (3.00%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN). Company Calendar Last Earnings8/07/2024Today3/10/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$170.41 High Stock Price Target$230.00 Low Stock Price Target$75.00 Potential Upside/Downside+70.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$2.28 Trailing P/E Ratio79.75 Forward P/E Ratio37.34 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins7.43% Pretax Margin7.89% Return on Equity11.00% Return on Assets3.35% Debt Debt-to-Equity Ratio0.93 Current Ratio3.84 Quick Ratio3.03 Sales & Book Value Annual Sales$1.90 billion Price / Sales5.09 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book10.85Miscellaneous Outstanding Shares97,032,000Free Float88,165,000Market Cap$9.67 billion OptionableOptionable Beta0.79 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SRPT) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.